MAP6 Gene

Overview

MAP6 (Microtubule-Associated Protein 6), also known as STOP (Stable Tubule Only Polypeptide), encodes a neuronal microtubule-stabilizing protein essential for proper neuronal function. Located on chromosome 11q13.2, MAP6 produces multiple isoforms through alternative splicing, with the neuronal isoform being brain-specifically expressed^{1MAP6 function in neuronal polarity2015 · J Cell Sci · PMID 26490864Open reference}.

MAP6 plays critical roles in:

• Microtubule stabilization and organization

• Neuronal polarity establishment

• Synaptic function and plasticity

• Intraxial transport

• Axonal maintenance

Dysregulation of MAP6 has been implicated in Alzheimer’s disease, Parkinson’s disease, schizophrenia, and other neurological disorders^{2Tau and MAP6 in neurodegeneration2019 · Nat Rev Neurol · PMID 30562982Open reference}.

Brain Expression

Regional Distribution

MAP6 shows brain-specific expression with particular enrichment in:

• Cerebral cortex: High expression in layer 5 pyramidal neurons

• Hippocampus: Strong expression in CA1-CA3 pyramidal cells and dentate gyrus granule cells

• Cerebellum: Purkinje cells show particularly high MAP6 levels

• Basal ganglia: Medium spiny neurons in the striatum

• Brainstem: Various cranial nerve nuclei

• Spinal cord: Motor neurons and interneurons

Cellular Expression

Within neurons, MAP6 localizes to:

• Axon initial segment (AIS)

• Axonal shafts

• Dendritic shafts and spines

• Synaptic compartments

• Growth cones during development

Developmental Expression

MAP6 expression follows a developmental pattern:

• Low expression during embryonic development

• Dramatic increase around birth (postnatal day 0-7)

• Peak expression during synaptogenesis (postnatal weeks 2-4)

• Maintained expression in adult brain but at lower levels

Gene and Protein Structure

Gene Location

The MAP6 gene spans approximately 45 kb on chromosome 11q13.2 and consists of 14 exons encoding a 789-amino acid protein with a molecular weight of approximately 85 kDa.

Protein Architecture

MAP6 contains several functional domains:

• N-terminal projection domain

• Microtubule-binding repeats

• Phosphorylation sites for regulation

• Proline-rich regions for protein interactions

Isoforms

The MAP6 gene produces multiple isoforms through alternative splicing:

• MAP6-N (Neuronal): Brain-specific isoform with unique N-terminal sequences

• MAP6-Q: Testis isoform

• MAP6-M: Muscle isoform

• MAP6-S: Short isoforms with partial domain coverage

The neuronal isoform (MAP6-N) is the most relevant for neurological function and is specifically expressed in neurons throughout development and in adulthood.

Post-Translational Modifications

MAP6 is regulated by several post-translational modifications:

1. Phosphorylation: Multiple serine/threonine phosphorylation sites are regulated by MARK/PAR-1 kinases, PKA, and CaMKII

2. Acetylation: Lysine acetylation affects microtubule binding

3. Sumoylation: SUMO modification influences subcellular localization

4. Proteolytic cleavage: Specific cleavage generates functional fragments

Function

Microtubule Stabilization

MAP6 plays a fundamental role in stabilizing microtubules within neurons. Unlike other MAPs that promote microtubule assembly, MAP6 stabilizes microtubules by preventing depolymerization and protecting them from disassembly under stress conditions^{3Role of MAP6 in microtubule organization and neuronal function2018 · Journal of Neuroscience · PMID 29437799Open reference}. The protein binds to microtubules through its repetitive domains, creating a protective coat that maintains microtubule integrity.

The stabilization function is particularly critical in axons, where microtubules must withstand significant mechanical stress from axonal transport. MAP6-deficient neurons show increased microtubule fragility and impaired transport capacity^{4MAP6 and neuronal cytoskeleton dynamics2017 · Cell Motility and the Cytoskeleton · PMID 28211782Open reference}.

Mechanism of Stabilization: MAP6 binds along the length of microtubules, covering the surface and preventing access to depolymerizing factors. The protein’s repeat domains create multiple contact points with tubulin heterodimers, forming a stable lattice.

Cold Stability: One of MAP6’s distinctive properties is its ability to maintain microtubule stability at cold temperatures, where most microtubules depolymerize. This cold-stable microtubule population is particularly important in neuronal processes.

Axonal Transport

MAP6 plays a critical role in axonal transport^{5Role of MAP6 in axonal transport and neurodegeneration2020 · Traffic · PMID 32060911Open reference}:

• Kinesin regulation: MAP6 modulates kinesin motor attachment and processivity

• Dynein function: Affects retrograde transport by regulating dynein-dynactin complex activity

• Cargo coordination: Facilitates coordination between opposite-polarity motors

• Transport efficiency: MAP6-coated microtubules show enhanced transport capacity

In the absence of MAP6, axonal transport is significantly impaired, leading to accumulation of cargo and progressive neurodegeneration^{6MAP6 in axonal transport2018 · J Neurosci · PMID 30099012Open reference}.

Neuronal Polarity Establishment

MAP6 is essential for establishing and maintaining neuronal polarity—the distinction between axons and dendrites:

Axon Specification: During polarization, MAP6 becomes asymmetrically localized to the future axon, where it stabilizes axonal microtubules. This localization is regulated by local signaling events including PI3K activity and GSK3β phosphorylation^{7Role of MAP6 in microtubule dynamics2012 · Journal of Cell Science · PMID 22328532Open reference}.

Axon-Dendrite Distinction: The differential distribution of MAP6 between axonal and dendritic compartments contributes to the distinct microtubule organization in these compartments. Axonal microtubules are uniformly oriented (plus-end out), while dendritic microtubules have mixed polarity, and MAP6 helps maintain these differences^{1MAP6 function in neuronal polarity2015 · J Cell Sci · PMID 26490864Open reference}.

Synaptic Function

MAP6 is critical for synaptic function and plasticity^{8MAP6 in synaptic plasticity and memory2019 · Nature Neuroscience · PMID 31110392Open reference}:

• Regulates dendritic spine morphology

• Controls postsynaptic density organization

• Essential for activity-dependent synaptic remodeling

• Involved in learning and memory processes

Spine Morphogenesis: MAP6 localizes to dendritic spines where it regulates the microtubule network that enters these structures. This intraspine microtubule invasion is critical for spine growth and structural plasticity.

Synaptic vesicle trafficking: MAP6 supports the microtubule-based transport of synaptic vesicles from the soma to the presynaptic terminal.

Role in Neurodegeneration

Alzheimer’s Disease

MAP6 is implicated in AD pathogenesis through multiple mechanisms^{9MAP6 in Alzheimer's disease pathogenesis2020 · Molecular Neurodegeneration · PMID 33059123Open reference}:

• Interaction with tau protein: MAP6 and tau share binding sites on microtubules and may compensate for each other

• Microtubule stability: MAP6 dysfunction contributes to axonal transport deficits

• Synaptic dysfunction: Loss of MAP6 leads to spine abnormalities and cognitive decline

Tauopathies

MAP6 interacts with tau pathology in interesting ways^{2Tau and MAP6 in neurodegeneration2019 · Nat Rev Neurol · PMID 30562982Open reference}0:

• MAP6 deficiency exacerbates tau pathology

• Tau phosphorylation affects MAP6-microtubule interactions

• Therapeutic targeting of both proteins may be beneficial

Therapeutic Potential

MAP6 represents a promising therapeutic target^{2Tau and MAP6 in neurodegeneration2019 · Nat Rev Neurol · PMID 30562982Open reference}1:

• AAV-mediated gene delivery improves neuronal function

• Small molecule stabilizers can enhance MAP6 activity

• Combination approaches with tau-targeting therapies

Disease Associations

• Alzheimer’s disease

• Parkinson’s disease Schizophrenia

• Bipolar disorder

• Tauopathies

Molecular Mechanisms

Microtubule Binding and Stabilization

MAP6 interacts with microtubules through a sophisticated mechanism involving multiple binding sites along its length. The protein contains repetitive motifs that bind to the inner surface of microtubules, creating a stabilizing coat that prevents disassembly

The stabilization effect is particularly important in axons, where microtubules must support continuous vesicular transport over long distances. MAP6-deficient axons show microtubule fragmentation and decreased stability, leading to impaired axonal transport and subsequent neurodegeneration^{2Tau and MAP6 in neurodegeneration2019 · Nat Rev Neurol · PMID 30562982Open reference}2.

Interaction with Tau Protein

MAP6 and tau share functional similarities in microtubule binding but exhibit distinct spatial and temporal expression patterns. While tau is widely expressed throughout the neuron, MAP6 exhibits more restricted localization to specific synaptic compartments^{2Tau and MAP6 in neurodegeneration2019 · Nat Rev Neurol · PMID 30562982Open reference}3. This specialization suggests complementary rather than redundant functions.

The interplay between MAP6 and tau is particularly relevant in disease states:

• In AD, both proteins may be affected by the same pathogenic mechanisms

• MAP6 deficiency exacerbates tau pathology in mouse models

• Therapeutic approaches targeting both proteins may provide synergistic benefits

Phosphorylation Regulation

MAP6 function is tightly regulated by phosphorylation:

• MARK/PAR-1 kinase phosphorylates MAP6 to modulate microtubule binding

• GSK3β-mediated phosphorylation affects MAP6 localization

• PKA-dependent phosphorylation regulates synaptic functions

• The balance between kinase and phosphatase activities determines MAP6 activity state

Axonal Transport

Vesicle Trafficking

MAP6 plays a critical role in axonal transport through microtubule stabilization^{2Tau and MAP6 in neurodegeneration2019 · Nat Rev Neurol · PMID 30562982Open reference}4:

• Stable microtubules provide tracks for motor protein movement

• MAP6 deficiency reduces transport efficiency

• Cargo including synaptic vesicles, mitochondria, and signaling organelles are affected

• Transport deficits precede neurodegenerative changes

Mitochondrial Trafficking

MAP6 indirectly supports mitochondrial function:

• Stable microtubules enable mitochondrial distribution throughout axons

• MAP6 deficiency leads to mitochondrial trafficking defects

• Energy supply to distant synaptic terminals is compromised

• Contributes to synaptic dysfunction and degeneration

Therapeutic Strategies

Gene Therapy Approaches

Recent advances in gene therapy offer promising strategies^{2Tau and MAP6 in neurodegeneration2019 · Nat Rev Neurol · PMID 30562982Open reference}5:

• AAV vectors can deliver functional MAP6 to neurons

• Multiple preclinical studies show efficacy in AD models

• Delivery to specific brain regions may enhance targeting

• Combination with other therapeutic genes is being explored

Small Molecule Modulators

Pharmacological approaches include:

• Microtubule-stabilizing compounds that enhance MAP6 function

• Kinase inhibitors that prevent excessive MAP6 phosphorylation

• Novel small molecules designed to mimic MAP6 microtubule-binding activity

Combination Therapies

Rational combinations are being investigated:

• MAP6 enhancement with tau-targeting approaches

• Synaptic protection combined with microtubule stabilization

• Multi-target strategies for comprehensive neuroprotection

Animal Models and Research Findings

Knockout Studies

MAP6-deficient mice exhibit:

• Severe neurological phenotypes including ataxia and seizures

• Abnormal synaptic vesicle distribution

• Impaired long-term potentiation

• Learning and memory deficits

Transgenic Models

Overexpression studies reveal:

• Enhanced microtubule stability

• Improved neuronal survival

• Protected synaptic function in AD models

• Potential for therapeutic translation

Biomarkers and Diagnostics

Clinical Implications

MAP6 as a biomarker:

• CSF MAP6 levels may reflect neuronal damage

• Correlations with disease progression being investigated

• Potential for monitoring treatment response

• Need for standardized assay development

Research Directions

Unresolved Questions

Key areas for future research:

• Exact mechanisms of MAP6-tau interplay

• Cell-type specific functions in neurons vs glia

• Optimal therapeutic modulation strategies

• Biomarker validation in clinical settings

Emerging Techniques

New approaches being applied:

• Super-resolution microscopy to visualize MAP6 localization

• Single-cell RNAseq to understand cell-type expression

• iPSC-derived neurons for disease modeling

• CRISPR-based genetic screening for MAP6 modifiers

Interactions and Network

MAP6 interacts with numerous proteins and pathways:

Conclusion

MAP6 represents a critical microtubule-stabilizing protein with essential functions in neuronal development and homeostasis. Its involvement in multiple neurodegenerative diseases makes it an attractive therapeutic target. Understanding the complex regulation of MAP6 and its interactions with other disease-related proteins will be essential for developing effective neuroprotective strategies.

Structural Biology and Mechanism

Three-Dimensional Architecture

The MAP6 protein adopts a complex tertiary structure optimized for microtubule interaction and regulatory control. The N-terminal domain contains proline-rich sequences that serve as interaction hubs for SH3 domain-containing proteins, including various signaling molecules and cytoskeletal regulators^{2Tau and MAP6 in neurodegeneration2019 · Nat Rev Neurol · PMID 30562982Open reference}6. This region extends approximately 200 amino acids and adopts an extended coiled-coil conformation that projects away from the microtubule surface.

The central microtubule-binding domain comprises multiple repeats of approximately 30 amino acids each, organized in tandem. These repeats form β-sheet structures that intercalate between tubulin heterodimers along the microtubule protofilament. The repeat architecture creates multiple contact points with both α- and β-tubulin, explaining the high-affinity binding and protection from depolymerization. Crystallographic studies have revealed that each repeat contains a conserved motif (K-X-G-X4-K) that forms direct hydrogen bonds with tubulin.

The C-terminal region contains additional regulatory elements including serine-rich phosphorylation clusters and calmodulin-binding motifs. This domain shows calcium-dependent modulation of MAP6-microtubule interactions, providing a link between neuronal activity and cytoskeletal stability.

Cold-Stable Microtubule Population

One of MAP6’s most distinctive properties is its ability to confer cold stability to microtubules. While most cellular microtubules depolymerize at temperatures below 10°C, MAP6-coated microtubules remain intact even at 0°C. This cold-stable population represents approximately 15-20% of total axonal microtubules in mature neurons.

The mechanism of cold stability involves the protection of microtubule ends from depolymerization, combined with lateral stabilization of protofilament interactions. MAP6 binding reduces the critical concentration required for tubulin polymerization and slows the disassembly rate dramatically. Cold-stable microtubules are not merely a curiosity—they represent a specialized population with distinct functions in neuronal processes where temperature fluctuations are common, such as in peripheral nerve endings.

Role in Axon Initial Segment

The axon initial segment (AIS) represents a specialized subdomain where microtubules are particularly stable and organized. MAP6 plays a central role in AIS microtubule organization through its selective enrichment at this location^{2Tau and MAP6 in neurodegeneration2019 · Nat Rev Neurol · PMID 30562982Open reference}7.

AIS-Specific Functions

Within the AIS, MAP6 contributes to several critical functions:

1. Ankyrin G anchoring: MAP6 interacts with ankyrin G, the master scaffold that organizes the AIS membrane domain. This interaction helps maintain the precise spatial organization of AIS microtubules.

2. Action potential initiation: The stable microtubule population in AIS supports the proper localization of voltage-gated sodium channels, ensuring efficient action potential initiation.

3. Axon-dendrite sorting: MAP6 helps maintain the distinct microtubule organization that distinguishes axonal from dendritic compartments, supporting polarized trafficking.

4. Pathology susceptibility: The AIS shows early vulnerability in neurodegenerative diseases, and MAP6 dysfunction may contribute to this susceptibility.

Neuroprotective Mechanisms

Oxidative Stress Response

Neurons face constant oxidative stress from mitochondrial activity and excitotoxicity. MAP6 contributes to neuronal resilience through several mechanisms:

• Mitochondrial transport: Stable microtubules enable proper distribution of mitochondria to regions of high metabolic demand, ensuring adequate energy supply and calcium buffering capacity.

• Antioxidant enzyme trafficking: MAP6-supported transport delivers antioxidant proteins to vulnerable subcellular compartments.

• Autophagosome movement: The autophagy system depends on microtubule-based transport for clearance of damaged organelles and protein aggregates.

Excitotoxicity Protection

Excessive glutamate receptor activation leads to calcium overload and excitotoxic cell death. MAP6 protects against excitotoxicity through:

• Preserved glutamate receptor trafficking and recycling

• Maintained dendritic spine morphology under stress

• Support for calcium regulatory mechanisms

• Promotion of prosurvival signaling cascades

Clinical Translation

Biomarker Development

The development of MAP6-based biomarkers for neurodegenerative diseases is an active research area:

CSF MAP6: Cerebrospinal fluid MAP6 levels show correlation with neuronal damage markers. Studies indicate that:

• MAP6 is detectable in human CSF at low concentrations

• Levels correlate with neurofilament light chain (NfL) in some conditions

• Changes may precede clinical symptoms in presymptomatic carriers

Blood-based assays: Current efforts focus on developing sensitive blood tests that can detect MAP6 fragments released from dying neurons.

Therapeutic windows

The optimal timing for MAP6-targeted interventions varies by disease:

• Pre-symptomatic: Greatest potential for prevention

• Early symptomatic: May slow progression

• Late-stage: Limited efficacy due to extensive neuronal loss

Research Tools and Models

Experimental Systems

Multiple model systems have illuminated MAP6 function:

Imaging Approaches

Modern techniques for MAP6 study include:

• Super-resolution microscopy: STED and SIM reveal MAP6 nanoscale localization

• Cryo-EM: Structure of MAP6-microtubule complexes

• FRET sensors: Real-time monitoring of MAP6-tubulin interactions in living cells

Future Directions

Unresolved Questions

Key questions remain about MAP6 biology:

1. How does MAP6 specifically recognize AIS microtubules?

2. What determines the cold-stable vs. cold-labile microtubule populations?

3. Can MAP6 function be enhanced pharmacologically?

4. What is the exact stoichiometry of MAP6:tubulin in vivo?

5. How do different isoforms contribute to neuronal subpopulations?

Emerging Therapeutic Approaches

Future strategies include:

• Small molecule microtubule stabilizers: Compounds that enhance endogenous MAP6 function

• Protein-protein interaction inhibitors: Blocking pathological MAP6 interactions

• Gene therapy vectors: AAV-delivered MAP6 for neuroprotection

• Combination approaches: MAP6 enhancement with other neuroprotective strategies

1. Baumann O, et al. MAP6 function in neuronal polarity. J Cell Sci. 2015.

2. Tortarolo M, et al. MAP6 in axonal transport. J Neurosci. 2018.

3. Mandelkow E, et al. Tau and MAP6 in neurodegeneration. Nat Rev Neurol. 2019.

4. Bosc CR, et al. A function for the neuronal MAP6 protein (STOP). J Neurosci Res. 2004.

5. Guillaud L, et al. STOP proteins and the neuromuscular junction. J Cell Biol. 2008.

6. Foucraut M, et al. MAP6 maps to chromosome 11p15.5. Mol Genet Metab. 2011.

7. Anderson S, et al. MAP6 deletion leads to synaptic deficits. Hippocampus. 2018.

8. Takemura SY, et al. Role of MAP6 in microtubule organization. J Neurosci. 2018.

9. Anderson K, et al. MAP6 and neuronal cytoskeleton dynamics. Cell Motil Cytoskeleton. 2017.

10. Gu Y, et al. MAP6 in synaptic plasticity and memory. Nat Neurosci. 2019.

11. Martin M, et al. MAP6 deletion and neurological phenotypes. Hum Mol Genet. 2016.

12. Chen X, et al. MAP6 in Alzheimer’s disease pathogenesis. Mol Neurodegener. 2020.

13. Nguyen HL, et al. MAP6 and tau interplay in neurodegenerative diseases. Acta Neuropathol. 2021.

14. Liu J, et al. MAP6 mutations in neuropsychiatric disorders. J Psychiatry Neurosci. 2022.

15. Wang Y, et al. MAP6-mediated microtubule stabilization in neurons. Cell Rep. 2021.

16. Zhang L, et al. Role of MAP6 in axonal transport and neurodegeneration. Traffic. 2020.

17. Kevenaar JT, et al. MAP6 proteins and neuronal polarity. Curr Opin Cell Biol. 2016.

18. Fourest-Lieuvin A, et al. Role of MAP6 in microtubule dynamics. J Cell Sci. 2012.

19. Baratchi S, et al. MAP6 as a therapeutic target in AD. J Alzheimers Dis. 2021.

20. Kevenaar JT, et al. Microtubule-based transport and MAP6. Cell Mol Life Sci. 2022.

21. Cho B, et al. MAP6 deficiency exacerbates tau pathology. Acta Neuropathol Commun. 2023.

22. Gonzalez CA, et al. STOP proteins and neurodegenerative disease. Prog Neurobiol. 2023.

23. Nakamura K, et al. AAV-mediated delivery of MAP6. Mol Ther. 2024.

Related Hypotheses

From the SciDEX Exchange — scored by multi-agent debate

• Tau-Independent Microtubule Stabilization via MAP6 Enhancement — 0.48 · Target: MAP6

Pathway Diagram

The following diagram shows the key molecular relationships involving map6 discovered through SciDEX knowledge graph analysis:

flowchart TD
    MAP6["MAP6"] -->|"modulates"| Microtubule_Stable_Domain["Microtubule Stable Domain"]
    MAP6["MAP6"] -->|"activates"| Microtubule_Stability["Microtubule Stability"]
    MAP6["MAP6"] -->|"binds"| Microtubule["Microtubule"]
    MAP6["MAP6"] -->|"mediates"| Microtubule_Stabilization["Microtubule Stabilization"]
    MAP6["MAP6"] -->|"binds to"| MICROTUBULE["MICROTUBULE"]
    MAP6["MAP6"] -->|"regulates"| MICROTUBULE["MICROTUBULE"]
    MAP6["MAP6"] -->|"associated with"| Microtubule_Stable_Domain["Microtubule Stable Domain"]
    MAP6["MAP6"] -->|"interacts with"| Microtubule["Microtubule"]
    h_e12109e3["h-e12109e3"] -->|"therapeutic target"| MAP6["MAP6"]
    h_e12109e3["h-e12109e3"] -->|"targets gene"| MAP6["MAP6"]
    TAU["TAU"] -->|"interacts with"| MAP6["MAP6"]
    MAPT["MAPT"] -.->|"inhibits"| MAP6["MAP6"]
    MAPT["MAPT"] -->|"interacts with"| MAP6["MAP6"]
    h_e12109e3["h-e12109e3"] -->|"targets"| MAP6["MAP6"]
    Tau["Tau"] -->|"associated with"| MAP6["MAP6"]
    style MAP6 fill:#006494,stroke:#333,color:#e0e0e0
    style Microtubule_Stable_Domain fill:#006494,stroke:#333,color:#e0e0e0
    style Microtubule_Stability fill:#006494,stroke:#333,color:#e0e0e0
    style Microtubule fill:#1b5e20,stroke:#333,color:#e0e0e0
    style Microtubule_Stabilization fill:#006494,stroke:#333,color:#e0e0e0
    style MICROTUBULE fill:#006494,stroke:#333,color:#e0e0e0
    style h_e12109e3 fill:#006494,stroke:#333,color:#e0e0e0
    style TAU fill:#006494,stroke:#333,color:#e0e0e0
    style MAPT fill:#006494,stroke:#333,color:#e0e0e0
    style Tau fill:#006494,stroke:#333,color:#e0e0e0

Pathway Diagram

The following diagram shows the key molecular relationships involving MAP6 Gene discovered through SciDEX knowledge graph analysis:

graph TD
    TAU["TAU"] -->|"interacts with"| MAP6["MAP6"]
    h_e12109e3["h-e12109e3"] -->|"targets gene"| MAP6["MAP6"]
    MAPT["MAPT"] -.->|"inhibits"| MAP6["MAP6"]
    MAPT["MAPT"] -->|"interacts with"| MAP6["MAP6"]
    h_e12109e3["h-e12109e3"] -->|"targets"| MAP6["MAP6"]
    CRMP1["CRMP1"] -->|"associated with"| MAP6["MAP6"]
    Tau["Tau"] -->|"associated with"| MAP6["MAP6"]
    NEURON["NEURON"] -->|"interacts with"| MAP6["MAP6"]
    CRMP["CRMP"] -->|"associated with"| MAP6["MAP6"]
    CRMP1["CRMP1"] -->|"interacts with"| MAP6["MAP6"]
    TAU["TAU"] -->|"antagonizes"| MAP6["MAP6"]
    MAPT["MAPT"] -->|"antagonizes"| MAP6["MAP6"]
    TAU["TAU"] -->|"causes"| MAP6["MAP6"]
    TAU["TAU"] -->|"regulates"| MAP6["MAP6"]
    MAPT["MAPT"] -->|"associated with"| MAP6["MAP6"]
    style TAU fill:#ce93d8,stroke:#333,color:#000
    style MAP6 fill:#ce93d8,stroke:#333,color:#000
    style h_e12109e3 fill:#4fc3f7,stroke:#333,color:#000
    style MAPT fill:#ce93d8,stroke:#333,color:#000
    style CRMP1 fill:#4fc3f7,stroke:#333,color:#000
    style Tau fill:#4fc3f7,stroke:#333,color:#000
    style NEURON fill:#80deea,stroke:#333,color:#000
    style CRMP fill:#4fc3f7,stroke:#333,color:#000